Staar Surgical Co: Form 10-K for the period ended Jan 3, 2020
Filed with the SEC on Feb 26, 2020 and accepted by EDGAR at Feb 26, 2020, 16:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-01-03. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-09-28 to 2020-01-03 | $38.9m | us-gaap:Revenues |
| Revenue | 12 months2018-12-29 to 2020-01-03 | $20.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2018-12-29 to 2020-01-03 | $38.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-09-28 to 2020-01-03 | $28.8m | us-gaap:GrossProfit |
| Gross profit | 12 months2018-12-29 to 2020-01-03 | $112.0m | us-gaap:GrossProfit |
| Research and development | 12 months2018-12-29 to 2020-01-03 | $25.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2018-12-29 to 2020-01-03 | $100.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2018-12-29 to 2020-01-03 | $11.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2018-12-29 to 2020-01-03 | −$1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-09-28 to 2020-01-03 | $6.4m | us-gaap:NetIncomeLoss |
| Net income | 12 months2018-12-29 to 2020-01-03 | $14.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-09-28 to 2020-01-03 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2018-12-29 to 2020-01-03 | $0.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-09-28 to 2020-01-03 | $0.14 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2018-12-29 to 2020-01-03 | $0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2018-12-29 to 2020-01-03 | 46,895,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2018-12-29 to 2020-01-03 | $25.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-12-29 to 2020-01-03 | $10.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-01-03 | $120.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-01-03 | $174.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-01-03 | $206.9m | us-gaap:Assets |
| Current liabilities | At period end2020-01-03 | $34.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-01-03 | $47.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-01-03 | $159.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-006791. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.